Distinct metastatic spread and progression patterns in patients treated with crizotinib for ROS1- and ALK-rearranged non-small cell lung cancer: a single-center retrospective study

BACKGROUND: Crizotinib has been approved for C-ros oncogene 1 (ROS1)- and anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) patients. Few studies have examined the differences in crizotinib treatment outcomes between these patients and the progression sites during treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Tomoaki, Yoshida, Tatsuya, Takeyasu, Yuki, Masuda, Ken, Sinno, Yuki, Matsumoto, Yuji, Okuma, Yusuke, Goto, Yasushi, Horinouchi, Hidehito, Yamamoto, Noboru, Ohe, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413025/
https://www.ncbi.nlm.nih.gov/pubmed/37577313
http://dx.doi.org/10.21037/tlcr-23-10

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413025/
https://www.ncbi.nlm.nih.gov/pubmed/37577313
http://dx.doi.org/10.21037/tlcr-23-10

Ejemplares similares